From Ghrelin Peptide to Drug-Like Molecule: The Design of JMV 2959, a Powerful Hunger Hormone Blocker

What the researchers found

This article describes the peptidomimetic design process that led to JMV 2959, a potent ghrelin receptor (GHS-R1a) antagonist built on a 1,2,4-triazole scaffold. Starting from the 28-amino-acid ghrelin peptide, the researchers progressively simplified the structure through medicinal chemistry to create a small-molecule antagonist. JMV 2959 has been extensively studied across multiple biological contexts, showing effects on food intake and obesity, addictive behaviors (including alcohol, nicotine, and drug reward), hyperactivity, and retinopathy.

Why it matters

Ghrelin is a key peptide hormone regulating appetite, metabolism, and reward pathways. JMV 2959 has become one of the most widely used research tools for studying ghrelin receptor function, and its development from a natural peptide to a drug-like small molecule illustrates the power of peptidomimetic design. The compound's effects on addiction are particularly noteworthy, as they suggest ghrelin signaling plays a role in reward-seeking behavior beyond food.

How the study worked

Peptidomimetic medicinal chemistry approach starting from the ghrelin peptide sequence and progressively modifying the structure to identify key pharmacophore elements. The 1,2,4-triazole was identified as a versatile scaffold for generating GHS-R1a ligands. JMV 2959 was then characterized in multiple in vitro binding assays and in vivo models covering food intake, addiction, hyperactivity, and retinopathy.

Who was studied

Review of in vitro and in vivo studies (preclinical animal models)

What this study cannot tell us

This is a highlight/review article describing prior work rather than presenting new data. JMV 2959 remains a research tool compound and has not advanced to clinical trials. The compound's effects across diverse biological models make it a valuable research tool but raise questions about selectivity and potential off-target effects.

How to read the evidence

This is a moderate-grade review/highlight article summarizing the development and preclinical characterization of JMV 2959. The compound has been validated across multiple independent studies and research groups, establishing it as a widely used pharmacological tool.

When this study was published

Published in 2013, this article describes foundational work in ghrelin receptor pharmacology. JMV 2959 continues to be widely used in research, and the peptidomimetic design principles described remain relevant to current drug development.

The bigger picture

JMV 2959 exemplifies how peptidomimetic chemistry transforms natural peptides into practical drug candidates. The ghrelin system has emerged as a major target not just for obesity but for addiction medicine — a connection that JMV 2959 helped establish. As ghrelin receptor-targeting drugs continue development, this foundational work illustrates the peptide-to-drug pipeline.

Questions still open

• Could ghrelin receptor antagonists like JMV 2959 be developed into clinical treatments for addiction or substance use disorders?
• What is the safety profile of chronic ghrelin receptor blockade — given ghrelin's broad physiological roles, would side effects limit therapeutic use?
• Can the peptidomimetic approach used for JMV 2959 be applied to develop orally available ghrelin receptor modulators with improved drug properties?

Common questions

Read the original research

The 1,2,4-triazole as a scaffold for the design of ghrelin receptor ligands: development of JMV 2959, a potent antagonist.

Amino acids, 44(2), 301-14

Citation

Moulin, Aline; Brunel, Luc; Boeglin, Damien; Demange, Luc; Ryan, Johanne; M'Kadmi, Céline; Denoyelle, Séverine; Martinez, Jean; Fehrentz, Jean-Alain. (2013). The 1,2,4-triazole as a scaffold for the design of ghrelin receptor ligands: development of JMV 2959, a potent antagonist.. Amino acids, 44(2), 301-14. https://doi.org/10.1007/s00726-012-1355-2